If you thought making Ibuprofen was complicated, IOLCP just showed how to turn it into a full-on vertical empire. Revenues hit ₹551.7 crore, up nearly 10% YoY, while profit after tax snuck up 14.4% to ₹34 crore (Q1 FY26 presentation). They even got the EU’s REACH registration for Acetic Anhydride—yes, that’s a big deal for exports to the continent.
Why does this matter now? Because IOLCP isn’t just playing in Ibuprofen anymore—they’re scaling Paracetamol, Metformin, and more, and acquiring 101 acres to fuel that growth. The specialty chemicals and API game is heating up globally, and this guy’s got a ~30% global share in Ibuprofen. Stick around—things get spicier two scrolls down.
AT A GLANCE
• Revenue ₹551.7 Cr – Up 9.8%, no Excel tricks here
• PAT ₹34 Cr – 14.4% jump, CFO smiling in the background
• EBITDA margin 12.4% – margins steady despite raw material costs
• Exports 24.4% – EU access unlocked with REACH certification
• Land bank 101 acres – ready to pump up production power
MANAGEMENT’S KEY COMMENTARY
Varinder Gupta, MD: “We are building the world’s only fully backward-integrated Ibuprofen chain. That’s how you own your costs and quality.” Translation: We don’t trust suppliers, so we make everything ourselves.
Vikas Gupta, Joint MD: “Non-Ibuprofen APIs now contribute 34%, aiming to increase export revenue to ~40%.” Translation: We’re diversifying because Ibuprofen alone can’t pay the bills forever.
Abhiraj Gupta, Executive Director: “Minoxidil project underway, fully funded internally.” Translation: We’re not waiting on external cash; growth is organic and controlled.
R&D Head: “50+ scientists working on eight new products in pipeline.” Translation: We’re cooking up pharma spells behind the lab doors.
Investor Relations: “EcoVadis Silver Medal for sustainability.” Translation: We recycle and look good doing it.
Board: “101 acres acquired near existing site, regulatory clearances underway.” Translation: Bigger factory, bigger money.
NUMBERS DECODED
Revenue – The Hero | ₹551.7 Cr in Q1 FY26, up 9.8% YoY; steady climb, no stunt doubles needed.
EBITDA – The Sidekick | ₹69.5 Cr with 12.4% margin, showing disciplined cost control despite inflation.
Margins – The Drama Queen | PAT margin 6.1%, modest but growing; watch this space as diversification kicks in.
ANALYST QUESTIONS
Q: What’s the export growth runway?
A: With 16 DMFs and 19 CEPs filed, Europe and regulated markets are the main targets. Expect exports to hit ~40%.
Q: Capex plans?
A: ₹5.5 crore on Minoxidil by Dec 2025; plus land acquisition means heavy lifting ahead.
Q: Any supply chain hiccups?
A: Backward integration is the answer—making raw materials in-house.
Q: Sustainability credentials?
A: EcoVadis Silver Medal and zero
